Pharmacists’ Knowledge and Attitudes Regarding Biologics and Biosimilars: A Literature Review
Abstract
Advancements in biologic therapies have become crucial for managing both acute and chronic illnesses. In addition, the growing presence of biosimilar medications presents significant opportunities for reducing healthcare costs and expanding patient access to essential biologic treatments. Pharmacists, as part of the healthcare system, play an important role in the use of this group of medications. The purpose of this literature review is to examine existing research on pharmacists’ knowledge and attitudes toward originator biologics and biosimilars, as well as assessing the need for further educational initiatives in this area.
A digital search of literature was carried out through journal databases, such as PubMed, and Scopus, using selected search terms, and applying the inclusion criteria that match the aim of the research. The majority of studies that are subject to evaluation have been conducted, in the form of short surveys, revealing that most of the pharmacists are familiar with the biologic and biosimilar medicines, however their measured knowledge was less extensive than their self-assessed knowledge. Pharmacists’ knowledge and attitudes towards biologics exhibit a wide variation. Insufficient clinical experience and need for additional education were identified as prerequisites for greater inclusion of biologic originator and biosimilar medicines in clinical practice.
References
Assessing the impact of promotion and advertising regulations on biosimilar uptake [Internet]. OECD Publishing; 2025 [cited 2026 Apr 14]. Available from: https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/12/assessing-the-impact-of-promotion-and-advertising-regulations-on-biosimilar-uptake_27d29388/c69f54b2-en.pdf
Biosimilar medicines: Overview [Internet]. European Medicines Agency (EMA); 2017 [cited 2026 Apr 15]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview.
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [Internet]. EUR-Lex; 2001 [cited 2026 Apr 15]. Available from: http://data.europa.eu/eli/dir/2001/83/oj.
The impact of biosimilar competition in Europe [Internet]. IQVIA Institute for Human Data Science; 2018 [cited 2026 Apr 15]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/iqvia-the-impact-of-biosimilar-competition-in-europe-2026-01-26-forweb.pdf
Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, TRS No 977 [Internet]. WHO; 2010 [cited 2026 Apr 15]. Available from: https://www.who.int/publications/m/item/sbp-trs-977-Annex-2.
Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527–40. doi: 10.1038/nrd3746.
Guideline on Immunogenicity assessment of therapeutic proteins [Internet]. EMA; 2017 [cited 2026 Apr 14]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.
Product- or Population-Specific Considerations II: Biological medicinal products, GVP [Internet]. EMA; 2016 [cited 2026 Apr 14]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products_en.pdf.
Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–7. doi: 10.1007/s40265-017-0717-1.
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–9. doi: 10.1016/S1470-2045(16)30374-6.
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–7. doi: 10.1182/blood-2012-04-425744.
Hung A, Vu Q, Mostovoy L. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? J Manag Care Spec Pharm. 2017;23(12):1234–44. doi: 10.18553/jmcp.2017.23.12.1234.
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. J Manag Care Spec Pharm. 2019;25(1):102–12. doi: 10.18553/jmcp.2019.25.1.102.
Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160–72. doi: 10.1007/s12325-016-0431-5.
Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharm Med. 2021;35(4):215–24. doi: 10.1007/s40290-021-00396-7.
Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, et al. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Res Int. 2018;2018:1–9. doi: 10.1155/2018/9597362.
Oqal M, Hijazi B, Alqudah A, Al-Smadi A, A Almomani B, Alnajjar R, et al. Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan. Int J Clin Pract. 2022;2022(1):8080308. doi: 10.1155/2022/8080308.
Sidikou, O. CP-108 Biosimilars: What do clinicians actually think? Eur J Hosp Pharm. 2016;23:A47–8. doi: 10.1136/ejhpharm.
Trajchuleski M, Naumovska Z, Ackova DG, Serafimovska MD, Lazarova B, Smilkov K. Medical specialists' knowledge and perceptions of biologicals and biosimilars: a literature review. Acad Med J. 2025;5(3):1–9.
Pasina, LNA. A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016;35:e31–3.
Adé A, Bourdon O, Bussières JF. A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France. Ann Pharm Fr. 2017;75(4):267–75. doi: 10.1016/j.pharma.2017.01.003.
O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–61. doi: 10.1016/j.yrtph.2017.06.013.
Beck M, Michel B, Rybarczyk-Vigouret MC, Levêque D, Sordet C, Sibilia J, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs. 2016;30(6):585–92. doi: 10.1007/s40259-016-0202-5.
Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1758835918818335. doi: 10.1177/1758835918818335.
Pawłowska I, Pawłowski L, Krzyżaniak N, Kocić I. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. BioDrugs. 2019;33(2):183–91. doi: 10.1007/s40259-019-00341-w.
Messner K, Eickhoff C, Schulz M, Allemann SS, Arnet I. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic. BMC Health Serv Res. 2023;23(1):1432. doi: 10.1186/s12913-023-10475-x.
Arnet I, Verbeek M, Almarsdóttir Anna B, Barbier L, Clifford R, Eickhoff C, et al. Community pharmacists’ preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. Explor Res Clin Soc Pharm. 2021;4:100084. doi: 10.1016/j.rcsop.2021.100084.
Poon SYK, Hsu JC, Ko Y, Chiang SC. Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan. Healthcare. 2021;9(11):1600. doi: 10.3390/healthcare9111600.
Hu Y, Song Z, Jiang D, Zhuo L, Cheng Y, Zhao R. Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey. Front Pharmacol. 2022;13:876503. doi: 10.3389/fphar.2022.876503.
Stevenson JG, McCabe D, McGrath M, McBride A. Pharmacist biosimilar survey reveals knowledge gaps. J Am Pharm Assoc. 2023;63(2):529–537. doi: 10.1016/j.japh.2022.11.001.
Giavatto C, Mourani J, Fitzpatrick C, Hardin B, Skrtic A, Evans A, et al. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy. J Manag Care Spec Pharm. 2024;30(2):175–82. doi: 10.18553/jmcp.2024.30.2.175.
Jarab AS, Al-Qerem W, Alzoubi KH, Abu Heshmeh SR, Al Hamarneh YN, Alefishat E, et al. Understanding Community Pharmacists’ Knowledge, Attitudes, and Practices Regarding Biosimilar Drugs: A Cross‐Sectional Survey. Int J Clin Pract. 2025;2025(1):2248512. doi: 10.1155/ijcp/2248512.
Ling YL, Gentile D, Kotomale A, Sharpe JA, Geli D, Gruben D, et al. Real-world familiarity with US biosimilar regulatory guidelines and interchangeability state laws among pharmacists and physicians treating immunological disorders. J Manag Care Spec Pharm. 2025;31(6):552–64. doi: 10.18553/jmcp.2025.31.6.552.
Shakeel S, Hassali MA, Rehman H, Rehman AU, Muneswarao J. Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists. Int J Gen Med. 2020;13:1075–82. doi: 10.2147/IJGM.S266545.
